Invisible bursts of heat from just a handful of living cells could soon reveal disease, infection and drug response far earlier than today’s laboratory tests.
Researchers at Harvard University have developed an ultra-sensitive pico-calorimeter that can measure the minute amounts of heat produced by living cells in real time, offering a new way to study cellular metabolism without the need for fluorescent labels or chemical markers.
The microfluidic device detects thermodynamic energy changes at the picowatt scale by measuring tiny temperature differences generated as cells consume nutrients and grow. Unlike conventional techniques that estimate metabolism indirectly through oxygen consumption or other proxy measurements, the new platform captures metabolic heat directly, providing a faster and more accurate picture of cellular activity.
To achieve this sensitivity, the researchers redesigned pico-calorimetry using an ultra-thin micromachined membrane fitted with three microscopic glass capillaries and an integrated thermopile. The capillary assembly is enclosed within a vacuum chamber to minimise heat loss and background interference, enabling the system to detect highly localised thermal changes with a response time of around eight seconds.
Laboratory tests demonstrated the sensor’s ability to monitor the growth of Escherichia coli populations containing as few as 30 to 40 bacterial cells. The platform also tracked bacterial responses to antibiotics including chloramphenicol, rifampicin and ampicillin by measuring changes in metabolic heat, allowing researchers to observe drug effects before visible changes in cell growth became apparent.
Beyond microbiology, the technology could support earlier diagnosis of conditions such as sepsis, where patients often have very low bacterial counts that are difficult to detect using conventional blood culture methods. Operating with nanolitre sample volumes, the sensor could identify metabolic activity and antibiotic susceptibility within hours rather than days.
The research team also believes the platform could benefit pharmaceutical development by enabling real-time monitoring of cell viability, proliferation, metabolism and drug response without the need for fluorescent dyes. Harvard’s Office of Technology Development has filed multiple patents covering the technology, while a spin-out company is working to commercialise the system for biomedical and clinical applications.
